Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, James Murray, David Calligaris, Sani Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria

Mol Cancer Ther (2015) 14 (12): 2735–2743.

https://doi.org/10.1158/1535-7163.MCT-15-0553

Published: 06 December 2015

View articletitled, Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Includes: Supplementary data

Journal Articles

Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.

James C. Murray, Huw D. Thomas, Philip Berry, Suzanne Kyle, Christopher Jones, Ruth Plummer, Alan V. Boddy, Nicola J. Curtin

Mol Cancer Ther (2013) 12 (11_Supplement): C75.

https://doi.org/10.1158/1535-7163.TARG-13-C75

Published: 01 November 2013

View articletitled, Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.

Journal Articles

Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.

Joshua W. Henshaw, Huiyu Zhou, Ashleigh Herriott, Miranda Patterson, Evelyn W. Wang, Don Musson, Johann de Bono, Lida A. Mina, Ramesh K. Ramanathan, Charles O'Neill, Andrew Dorr, Nicola J. Curtin

Mol Cancer Ther (2013) 12 (11_Supplement): A220.

https://doi.org/10.1158/1535-7163.TARG-13-A220

Published: 01 November 2013

View articletitled, Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.

Journal Articles

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell, Nicola J. Curtin

Mol Cancer Ther (2013) 12 (6): 959–967.

https://doi.org/10.1158/1535-7163.MCT-12-0707

Published: 09 June 2013

View articletitled, Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Journal Articles

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Joanne M. Munck, Michael A. Batey, Yan Zhao, Helen Jenkins, Caroline J. Richardson, Celine Cano, Michele Tavecchio, Jody Barbeau, Julia Bardos, Liam Cornell, Roger J. Griffin, Keith Menear, Andrew Slade, Pia Thommes, Niall M.B. Martin, David R. Newell, Graeme C.M. Smith, Nicola J. Curtin

Mol Cancer Ther (2012) 11 (8): 1789–1798.

https://doi.org/10.1158/1535-7163.MCT-11-0535

Published: 08 August 2012

View articletitled, Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Includes: Supplementary data

Journal Articles

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin, Kaye J. Williams

Mol Cancer Ther (2011) 10 (12): 2320–2329.

https://doi.org/10.1158/1535-7163.MCT-11-0356

Published: 07 December 2011

View articletitled, The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

Includes: Supplementary data

Journal Articles

Abstract A77: Efficacy of PARP inhibitor AG014699 in orthotopic GBM xenografts is limited by ineffective drug penetration into the central nervous system.

Ling Cen, Brett L. Carlson, Mark A. Schroeder, James Murray, Julieann Sludden, Alan V. Boddy, Nicola J. Curtin, Jann Sarkaria

Mol Cancer Ther (2011) 10 (11_Supplement): A77.

https://doi.org/10.1158/1535-7163.TARG-11-A77

Published: 12 November 2011

View articletitled, Abstract A77: Efficacy of PARP inhibitor AG014699 in orthotopic GBM xenografts is limited by ineffective drug penetration into the central nervous system.

Journal Articles

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

Huw D. Thomas, Kappusamy Saravanan, Lan-Zhen Wang, Mei-Ju Lin, Julian S. Northen, Hannah Barlow, Marion Barton, David R. Newell, Roger J. Griffin, Bernard T. Golding, Nicola J. Curtin

Mol Cancer Ther (2009) 8 (7): 1828–1837.

https://doi.org/10.1158/1535-7163.MCT-08-1208

Published: 14 July 2009

View articletitled, Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

Includes: Supplementary data

Journal Articles

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Michelle J. Clarke, Evan A. Mulligan, Patrick T. Grogan, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Nicola J. Curtin, Zhenkun Lou, Paul A. Decker, Wenting Wu, E. Ruth Plummer, Jann N. Sarkaria

Mol Cancer Ther (2009) 8 (2): 407–414.

https://doi.org/10.1158/1535-7163.MCT-08-0854

Published: 11 February 2009

View articletitled, Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Journal Articles

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Huw D. Thomas, Christopher R. Calabrese, Michael A. Batey, Stacie Canan, Zdenek Hostomsky, Suzanne Kyle, Karen A. Maegley, David R. Newell, Donald Skalitzky, Lan-Zhen Wang, Stephen E. Webber, Nicola J. Curtin

Mol Cancer Ther (2007) 6 (3): 945–956.

https://doi.org/10.1158/1535-7163.MCT-06-0552

Published: 15 March 2007

View articletitled, Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.

Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

Abstract A77: Efficacy of PARP inhibitor AG014699 in orthotopic GBM xenografts is limited by ineffective drug penetration into the central nervous system.

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only